Abstract
Background: The transmembrane receptor C-type lectin domain family 12, member A (CLEC12A) is known to be highly expressed on monocytes and neutrophils and is a reliable leukemia associated marker in acute myeloid leukemia. Consequently, detailed knowledge of the various normal cell types expressing this receptor is essential. We have observed CLEC12A to be expressed on CD45lowSSClowCD14-CD123+ basophils in peripheral blood (PB) and in the present study, we aimed at verifying this observation and further delineate the CD45lowSSClowCD14-CD123+CLEC12A+ subpopulation.
Methods: We analyzed PB from 20 diagnostic chronic myeloid leukemia (CML) samples and 8 healthy donors in a 6 color multicolor flowcytometry (FCM) based assay. Furthermore, we performed fluorescence activated cell sorting on one CML sample to morphologically confirm the CD45lowSSClowCD14-CD123+CLEC12A+ subset to be highly enriched for basophils. Finally, to further delineate the CD45lowSSClowCD14-CD123+CLEC12A+ subpopulation in normal PB, we examined 3 healthy donors in a 10-color FCM assay enabling further separation of the cell subset into basophils and dendritic cells.
Results: The CLEC12A receptor is expressed on basophils.
Conclusions: Identification and enumeration of basophils is of high relevance in diagnostic hematology and immunology. We here show that CLEC12A in a simple FCM assay consistently marks basophils. Importantly, since basophils are characterized by a CD45lowSSClow profile similar to the “blast-gate” employed for the evaluation of hematological disorders, awareness of minor normal CLEC12A+ subpopulations is crucial when using CLEC12A as a minimal residual disease marker in myeloid malignancies.
Methods: We analyzed PB from 20 diagnostic chronic myeloid leukemia (CML) samples and 8 healthy donors in a 6 color multicolor flowcytometry (FCM) based assay. Furthermore, we performed fluorescence activated cell sorting on one CML sample to morphologically confirm the CD45lowSSClowCD14-CD123+CLEC12A+ subset to be highly enriched for basophils. Finally, to further delineate the CD45lowSSClowCD14-CD123+CLEC12A+ subpopulation in normal PB, we examined 3 healthy donors in a 10-color FCM assay enabling further separation of the cell subset into basophils and dendritic cells.
Results: The CLEC12A receptor is expressed on basophils.
Conclusions: Identification and enumeration of basophils is of high relevance in diagnostic hematology and immunology. We here show that CLEC12A in a simple FCM assay consistently marks basophils. Importantly, since basophils are characterized by a CD45lowSSClow profile similar to the “blast-gate” employed for the evaluation of hematological disorders, awareness of minor normal CLEC12A+ subpopulations is crucial when using CLEC12A as a minimal residual disease marker in myeloid malignancies.
| Original language | English |
|---|---|
| Pages (from-to) | 520-526 |
| Number of pages | 7 |
| Journal | Cytometry Part B: Clinical Cytometry |
| Volume | 94 |
| Issue number | 3 |
| Early online date | 11 Aug 2017 |
| DOIs | |
| Publication status | Published - May 2018 |
Bibliographical note
The authors gratefully acknowledge Professor Peter Hokland, Department of Hematology, Aarhus University Hospital for continuous support. This study was financially supported by the Danish Cancer Society. All authors declare no relevant conflicts of interest.Funded by
Danish Cancer Society. Grant Number: R90-A6080
Keywords
- CLEC12A
- CD371
- hMICL
- basophils
- immunophenotyping
Access to Document
- Accepted Manuscript
This is the peer reviewed version of the following article: Toft-Petersen, M, Stidsholt Roug, A, Plesner, T, Ebbesen, L, Brown, GD & Nederby, L 2018, 'The CLEC12A receptor marks human basophils: Potential implications for minimal residual disease detection in acute myeloid leukemia' Cytometry Part B: Clinical Cytometry, vol 94, no. 3, pp. 520-526., which has been published in final form at DOI 10.1002/cyto.b.21540. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.